The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program

被引：2
|
作者：
Silberstein, S. [1 ]
Dodick, D. W. [2 ]
DeGryse, R. E. [3 ]
Lipton, R. [4 ]
Turkel, C. C. [3 ]
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Mayo Clin Arizona, Phoenix, AZ USA
[3] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
[4] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2013年 / 14卷
关键词：
Migraine; Treatment Cycle; Chronic Migraine; Migraine Patient; Responder Rate;
D O I：
10.1186/1129-2377-14-S1-P200
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
    S Silberstein
    DW Dodick
    RE DeGryse
    R Lipton
    CC Turkel
    The Journal of Headache and Pain, 2013, 14
  • [2] OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
    Aurora, S. K.
    Dodick, D. W.
    Diener, H. -C.
    DeGryse, R. E.
    Turkel, C. C.
    Lipton, R. B.
    Silberstein, S. D.
    ACTA NEUROLOGICA SCANDINAVICA, 2014, 129 (01): : 61 - 70
  • [3] OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
    Isabel Pedraza, Maria
    de la Cruz, Carolina
    Ruiz, Marina
    Lopez-Mesonero, Luis
    Martinez, Elena
    de Lera, Mercedes
    Luis Guerrero, Angel
    SPRINGERPLUS, 2015, 4
  • [4] OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program
    Aurora, Sheena K.
    Winner, Paul
    Freeman, Marshall C.
    Spierings, Egilius L.
    Heiring, Jessica O.
    DeGryse, Ronald E.
    VanDenburgh, Amanda M.
    Nolan, Marissa E.
    Turkel, Catherine C.
    HEADACHE, 2011, 51 (09): : 1358 - 1373
  • [5] OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
    Aurora, S. K.
    Dodick, D. W.
    DeGryse, R. E.
    Turkel, C. C.
    JOURNAL OF HEADACHE AND PAIN, 2013, 14
  • [6] OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
    SK Aurora
    DW Dodick
    RE DeGryse
    CC Turkel
    The Journal of Headache and Pain, 2013, 14
  • [7] Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
    Michael Bjørn Russell
    The Journal of Headache and Pain, 2011, 12 : 135 - 136
  • [8] Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program
    Blumenfeld, Andrew
    Silberstein, Stephen D.
    Dodick, David W.
    Aurora, Sheena K.
    Turkel, Catherine C.
    Binder, William J.
    HEADACHE, 2010, 50 (09): : 1406 - 1418
  • [9] EARLY AND SUSTAINED EFFECT OF ONABOTULINUMTOXINA FOR CHRONIC MIGRAINE TREATMENT: ANALYSIS OF PREEMPT DATA
    Dodick, David W.
    Silberstein, Stephen D.
    Lipton, Richard B.
    DeGryse, Ronald E.
    Adams, Aubrey Manack
    Diener, Hans-Christoph
    TOXICON, 2018, 156 : S23 - S24
  • [10] Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis
    Diener, Hans-Christoph
    Dodick, David W.
    Lipton, Richard B.
    Sommer, Katherine
    Silberstein, Stephen D.
    TOXICON, 2022, 214 : S15 - S16
12345